Sodium Acetate Injection, USP: Particulate matter
Last updated
Summary
Product
Sodium Acetate Injection, USP
Issue
Health products - Product quality
What to do
See instructions below.
Affected products
Brand |
Product Name |
Market Authorization |
Dosage Form |
Strength |
Lot |
|---|---|---|---|---|---|
Sodium Acetate Injection, USP |
Sodium Acetate Injection, USP |
DIN 02139529 |
Solution |
Sodium Acetate 328 MG/ML |
6125334, 6125335 |
Issue
Presence of particulate matter in affected lots.
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Wholesalers, Healthcare Establishments
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
Fresenius Kabi Canada Ltd.
165 Galaxy Boulevard Suite 100,
Toronto, Ontario,
M9W 0C8
Published by
Health Canada
Audience
General public
Healthcare
Industry
Recall class
Type I
Identification number
RA-63965
Get notified
Receive notifications for new and updated recalls and alerts by category.